Kristin is an actual GILENYA patient.
She is compensated for her time.
Are you ready to fight back?
At any sign of disease activity,
fight back with GILENYA1
In relapsing forms of multiple sclerosis
The only pill proven to reduce relapse rates by more than half vs Avonex®1-5
52 %
relative reduction
in ARR vs Avonex
(0.16 vs 0.33; P<0.001)1,2
54 %
relative reduction
in ARR vs placebo
(0.18 vs 0.40; P<0.001)1,6

Important Safety Information


  • Patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure (HF) requiring hospitalization or Class III/IV HF
  • History or presence of Mobitz Type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome, unless patient has a functioning pacemaker
  • Baseline QTc interval ≥500 msec
  • Treatment with Class Ia or Class III anti-arrhythmic drugs

Bradyarrhythmia and AV Block: Monitor patients during GILENYA initiation because of a risk of bradyarrhythmia and AV block. Observe all patients for signs and symptoms of bradycardia for at least 6 hours after first dose with hourly pulse and blood pressure (BP) measurement. Obtain an electrocardiogram (ECG) prior to dosing and at the end of the observation period. Patients who develop a heart rate (HR) <45 bpm or new onset second degree or higher AV block should be monitored until resolution. Patients at lowest post-dose HR at end of observation period should be monitored until HR increases. Begin continuous ECG monitoring in patients with symptomatic bradycardia, and if pharmacological intervention is needed, continue ECG monitoring overnight in a medical facility, and repeat first-dose monitoring for second dose. Some patients may experience a second decrease in HR within 24 hours after the first dose.

Patients with pre-existing ischemic heart disease, history of MI or cardiac arrest, CHF, cerebrovascular disease, uncontrolled hypertension, history of symptomatic bradycardia or recurrent syncope, severe untreated sleep apnea, AV block, sinoatrial heart block, and patients on concomitant drugs that slow HR or AV conduction should be evaluated by a physician and, if treated with GILENYA, monitored overnight with continuous ECG in a medical facility after the first dose due to higher risk of symptomatic bradycardia or heart block. Patients with or at risk for QT prolongation or on concomitant QT-prolonging drugs with a known risk of torsades de pointes should also be monitored overnight with continuous ECG. If GILENYA is discontinued for >14 days after the first month of treatment, the effects on HR and AV conduction may recur on reintroduction of treatment and the same precautions for initial dosing should apply. Take the same precautions if treatment is interrupted ≥1 day within the first 2 weeks or for >7 days during weeks 3 and 4.

Infections: GILENYA may increase the risk of infections. A recent CBC should be available before initiating GILENYA. Consider suspending GILENYA if a patient develops a serious infection. Monitor for signs and symptoms of infection during treatment and up to 2 months after discontinuation. Do not start GILENYA in patients with active acute or chronic infections. Two patients receiving a higher dose of GILENYA (1.25 mg) in conjunction with high-dose corticosteroid therapy died of herpetic infections. Cryptococcal infections, including cases of cryptococcal meningitis, have been reported with GILENYA in the postmarketing setting. Patients with symptoms and signs consistent with cryptococcal meningitis should undergo prompt diagnostic evaluation and treatment. Concomitant use with antineoplastic, immunosuppressive, or immune-modulating therapies would be expected to increase the risk of immunosuppression. To avoid additive immunosuppressive effects, consider the duration of effect and mode of action of such therapies.

Before initiating GILENYA, patients without a history of chickenpox or without vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV. VZV vaccination of antibody-negative patients is recommended prior to commencing GILENYA treatment, following which GILENYA initiation should be postponed for 1 month.

Progressive Multifocal Leukoencephalopathy: A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the postmarketing setting. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.

Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. MRI signs may be apparent before clinical symptoms.

At the first sign or symptom suggestive of PML, withhold GILENYA and perform an appropriate diagnostic evaluation.

Macular Edema: Fingolimod increases the risk of macular edema, with or without visual symptoms. Perform an exam of the fundus, including the macula, before starting GILENYA and at 3 to 4 months after initiation. Monitor visual acuity at baseline and during routine patient evaluations. Patients with diabetes mellitus or history of uveitis are at increased risk and should have regular ophthalmologic evaluations.

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported with GILENYA. Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, GILENYA should be discontinued.

Respiratory Effects: Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in GILENYA patients as early as 1 month after initiation. The changes in FEV1 appear to be reversible after discontinuing GILENYA; however, there is insufficient information to determine the reversibility of DLCO. Obtain spirometry and DLCO when clinically indicated.

Liver Injury: Recent liver transaminase and bilirubin levels should be available before initiating GILENYA. Elevations 3- and 5-fold the upper limit of normal have occurred with GILENYA. The majority occurred within 6 to 9 months and returned to normal within 2 months after discontinuing GILENYA. Recurrence of liver transaminase elevations occurred with rechallenge in some patients. Assess liver enzymes if symptoms suggestive of hepatic injury develop. Discontinue GILENYA if significant liver injury is confirmed.

Fetal Risk: GILENYA may cause fetal harm. Women of childbearing potential should use effective contraception during and for 2 months after stopping GILENYA. A registry for women who become pregnant during GILENYA treatment is available. Contact the GILENYA Pregnancy Registry by calling OUTCOME at 1‑877‑598‑7237, sending an e-mail to gpr@outcome.com, or accessing gilenyapregnancyregistry.com.

Blood Pressure Effects: BP should be monitored during treatment with GILENYA. An average increase over placebo of 3 mm Hg in systolic and 2 mm Hg in diastolic BP was observed in clinical trials.

Immune System Effects Following Discontinuation: Fingolimod remains in the blood and has pharmacodynamic effects, including decreased lymphocyte counts, for up to 2 months following the last dose. Lymphocyte counts generally return to normal range within 1 to 2 months of stopping therapy. Initiating other drugs during this period warrants the same considerations needed for concomitant administration.

Drug Interactions: Closely monitor patients receiving systemic ketoconazole. The use of live attenuated vaccines should be avoided during and for 2 months after stopping GILENYA.

Common Adverse Reactions: The most common adverse reactions with GILENYA (incidence ≥10% and >placebo) compared with placebo were headache, liver transaminase elevations, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.


GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

ARR=annualized relapse rate.

References: 1. Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2015. 2. Cohen JA, Barkhof F, Comi G, et al; for TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
3. Aubagio [prescribing information]. Cambridge, MA: Genzyme Corp; October 2014a. 4. Tecfidera [prescribing information]. Cambridge, MA: Biogen Idec Inc.; April 2015. 5. Miller D, Fox R, Phillips JT, et al. Effects of BG-12 on magnetic resonance imaging (MRI) endpoints in patients with relapsing-remitting multiple sclerosis (RRMS): data from the phase 3 CONFIRM study. Neurology. 2012;78(suppl 1):S11.001. 6. Kappos L, Radue E-W, O'Connor P, et al; for FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.

GILENYA is a registered trademark of Novartis AG.
Avonex is a registered trademark of Biogen.

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2015 Novartis 8/15 GYA-1319279